MedTrace Logo

Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection

NCT02027116 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2017-08-07

No results posted yet for this study

Summary

To evaluate the safety, tolerability and immunogenicity of VGX-6150 as second-line therapy in chronic hepatitis C patients

Conditions

  • Hepatitis C, Chronic

Interventions

BIOLOGICAL

VGX-6150

Plasmid DNA delivered via IM injection with electroporation

Sponsors & Collaborators

Principal Investigators

  • Sang Hoon Ahn, M.D, Ph.D. · Severance Hospital

  • Jeong Heo, M.D, Ph.D. · Pusan National University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-07-31
Completion
2017-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02027116 on ClinicalTrials.gov